Abstract: Pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose−2-alkylsulfanyl-1,3-oxazoline (Glc-PSO) structure exhibit an unprecedented specificity as inhibitors of mammalian β-glucosidase. Notably, their inhibitory potency against human β-glucocerebrosidase (GCase) was found to be strongly dependent on the nature of aglyconetype moieties attached at the sulfur atom. In the particular case of ω-substituted hexadecyl chains, an amazing influence of the terminal group was observed. A comparative study on a series of Glc-PSO derivatives suggests that hydrogen bond acceptor functionalities, e.g. fluoro * Corresponding authors. Y.D., Tel.: +34 9 775 58151; fax: +34 9 7755 8446. E-mail: yolanda.diaz@urv.cat M.C.O., Tel.: +34 9 5455 9806; fax: +34 9546 24960. E-mai: mellet@us.es or methyloxycarbonyl, significantly stabilize the Glc-PSO:GCase complex. The S-(16-flurohexadecyl)-PSO glycomimetic turned out to be a more potent GCase competitive inhibitor than ambroxol, a non glycomimetic drug currently in pilot trials as a pharmacological chaperone for Gaucher disease. Moreover, the inhibition constant increase by one order of magnitude when shifting from neutral (pH 7) to acidic (pH 5) media, a favorable characteristic for a chaperone candidate. Indeed, the fluoro-PSO derivative also proved superior to ambroxol in mutant GCase activity enhancement assays in N370S/N370S Gaucher fibroblasts. The results represent a proof of concept of the potential of exploiting long-range non-glycone interactions in glycosidase inhibitor/chaperone design.
Introduction
The search for compounds capable of modulating the activity of glycosidases, the enzymes that catalyze the hydrolysis of the glycosidic bond in polysaccharides and glycoconjugates, represents one of the more active research fields in glycobiology [1] . Glycosidase inhibitors are fundamental tools to interrogate biological processes involving biosynthesis, metabolism and recognition of carbohydrates [2] and bear strong potential for the development of drugs against associated pathologies [3] , including cancer [4] [5] [6] [7] [8] , diabetes [9, 10] , infection [11] [12] [13] , ischemia [14] or neurodegenerative diseases [15, 16] . On the other hand, compounds stabilizing the proper folding of trafficking-incompetent mutant glycosidases at the endoplasmid reticulum (ER), thereby rescuing them from degradation by the quality control system of the cell, show high promise as pharmacological chaperones for the treatment of lysosomal storage disorders [17] [18] [19] [20] [21] such as Gaucher [22] [23] [24] [25] [26] [27] , Fabry [28] [29] [30] or G M1 gangliosidosis [31] [32] [33] [34] , formally acting as effectors of the corresponding dysfunctional enzyme. Someway counterintuitively, the glycosidase inhibitory and chaperoning activities often coexist, the balance between them being a function of concentration and relative binding affinities at neutral (ER) and acidic pH (lysosome) [35] .
With few exceptions [36] [37] [38] [39] [40] , most naturally occurring or de novo synthesized glycosidase inhibitors/chaperones are carbohydrate-like derivatives (glycomimetics) in which the acetal group characteristic of glycosides has been modified while preserving a hydroxylation pattern of stereochemical complementarity with the aglycone moiety of the putative glycosidase substrate.
Yet, recent work has shown the importance of implementing non-glycone interactions to achieve glycosidase selectivity levels within isoenzymes compatible with clinical applications [41] [42] [43] [44] [45] [46] [47] .
Most of the work in this sense has focused on nitrogen-(iminosugars [48, 49] , 16 sp 2 -iminosugars [50] [51] [52] [53] [54] [55] [56] [57] [58] , azasugars [59, 60] ) and carbon-in-the-ring (carbasugars [61, 62] , cyclitols [63, 64] ) carbohydrate mimics. Surprisingly, aglycon effects for glycomimetics keeping the pyranose core intact have been much less studied [65] [66] [67] [68] , even though modifications at the glycosidic region has the potential to be compatible with molecular diversity-oriented strategies with a relatively low synthetic cost [69] .
In a previous report [70] , we developed a new family of pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose−2-alkylsulfanyl-1,3-oxazoline structure (Glc-PSO, Figure imposes a skew-boat conformation to the pyranose ring, which has been found to impart glycosidase transition state mimic character [72] . Structure-chaperone activity relationship studies on fibroblasts from Gaucher disease patients evidenced a strong impact of the nature of exocyclic S-substituents of Glc-PSO glycomimetics on the mutant lysosomal β-glucosidase (β-glucocerebrosidase; GCase) effector abilities. Notably, the S-(16-hydroxyhexadecyl) derivative (Glc-PSO-HHD) was as efficient as the non-glycomimetic chaperone candidate ambroxol (ABX), currently in pilot trials in humans [73] , for the N370S homozygous GCase mutation, the most prevalent for this lysosomal storage disorder. The possibility of hydrogen bonding involvement of the terminal hydroxyl group, once the pyranoid ring sits in the active site of the enzyme, with an amino acid residue located at an appropriate distance was advanced. To test this hypothesis, we have now expanded the PSO family with the preparation of a series of analogues keeping the hexadecyl chain in the aglycone but modifying the terminal group or the configuration of the core. The synthetic strategy and the evaluation of the new compounds as glycosidase inhibitors and chaperone candidates are reported. Figure 1 . General structure of Glc-PSO glycomimetics, structures of the related glycosidase inhibitors NAG-thiazoline, NBuGT and thiamet-G and structure of the previously reported Glc-PSO derivative Glc-PSO-HHD, which exhibited pharmacological chaperone abilities towards human glucocerebrosidase in Gaucher disease fibroblasts.
Results
The preparation of PSO glycomimetics with a hydroxylation profile matching that of D-glucose and differing in the S-linked aglycon portion relies on the S-alkylation reaction of the pivotal 1,3-oxazolidine-2-thione glucopyranose intermediate 1.
Taking into consideration that the target enzyme GCase has been shown to exhibit low discriminating capabilities between active sitebinding ligands differing in the configuration at C-4 for some glycomimetic families [74] , the corresponding D-galacto configured epimer 2 was also initially considered. The methodology used for the synthesis of 1 and 2 starts from tri-O-acetyl-D-glucal (3) or -D-galactal (5), respectively, and involved epoxidation of the double bond with in situ generated dimethyldioxirane. In the first case, the reaction afforded a mixture of the α-D-gluco-and β-Dmanno-configured tri-O-acetyl-1,2-anhydrosugars 4 (D-gluco/D-manno ratio 7:1) in 90 % yield [75] . Epoxidation of 5 provided instead exclusively the α-epoxide 6 (α-D-galacto configuration) in an almost quantitative yield [75] . Reaction of 4 and 6 with potassium thiocyanate and catalytic amounts of TiO(CH 3 CO 2 ) 2 led to the requested thionocarbamates 1 and 2 in 87 and 79% yield, respectively [76, 77] (Scheme 1).
Scheme 1. Synthesis of 1,3-oxazolidine-2-thione glycopyranose derivatives 1 and 2.
In view of the good GCase chaperon properties observed for the D-gluco-PSO derivative bearing an S-(ω-hydroxyhexadecyl) aglycon moiety Glc-PSO-HHD ( Figure 1 ) and the significant contribution of the terminal hydroxyl to this behaviour [70] , in this work we have chosen to examine the incorporation of a series of ω-substituted hexadecyl chains bearing different terminal groups, including ester, carboxylic acid, iodo and fluoro. These compounds were prepared using the corresponding distal iodo derivatives as the alkylating agents. Methyl 16-iodohexadecanoate and 16-iodohexadecanoic acid were prepared from the corresponding commercially available 16-bromo derivatives by reaction with sodium iodide in acetone (see Supporting Information). Given the ambident character of the thionocarbamate functionality [78] , the reaction conditions for the alkylation step had to be carefully adjusted in order to warrant the alkylation reaction regioselectively at the sulfur atom. Thus, compound 1 was treated with a series of different alkyl iodides in dichloromethate in the presence of triethylamine and N,Ndimethylaminopyridine (DMAP) following the work by Rollin et al. [79, 82] . Reactions carried out under these soft conditions afforded the expected acetyl-protected PSO derivatives 7-10 in 52-87 % yields (Table 1) . Interestingly, reaction of 1 with 1,16-diiodohexadecane not only afforded the expected S-(16-iodohexadecyl)sulfanyl derivative 8, but also the dialkylation product 9, isolated in 32 % yield (Table 1 , entry 2). We also prepared the corresponding D-galacto-PSO derivative 11, bearing the S-(16-hydroxyhexadecyl) antenna, to test the effect of the configurational change on the inihibitory/chaperone properties.
The S-alkyl character of compounds 7-11 was confirmed by The target fully-unprotected PSOA-glycomimetics 12-16 were obtained in 81-100 % yield by final removal of the acetyl protecting groups using methanol under standard NaOMe-catalyzed conditions. In order to obtain derivative 17, precursor 7 was treated with a solution of sodium hydroxide in methanol under similar reactions conditions (Table 1 , entry 2). The vicinal protonproton coupling constants about the pyranose ring both for the acetylayed (7-11) and the unprotected (12-17) PSO derivatives were in agreement with a skew-boat conformation close to 0 S 2 as previously observed for us [70] and others [83, 84] in structurally related bicyclic cis-1,2-fused glucopyranose structures in solution. 
Biological evaluation
The new PSO derivatives 12-17 were first screened as inhibitors against a panel of commercial glycosidases including α-glucosidase (yeast), β-glucosidase (β-Glcase; almonds and bovine liver, cytosolic), α-mannosidase (Jack bean), β-mannosidase (Helix pomatia), trehalase (pig kidney), amyloglucosidase (Aspergillus niger), naringinase (β-glucosidase/α-L-rhamnosidase, Penicillium decumbens), α-galactosidase (green coffee beans), β-galactosidase (E. coli), and amyloglucosidase (Aspergillus niger). All compounds behaved as competitive inhibitors of the mammalian β-Glcase and exhibited total selectivity within the series of enzymes assayed; a unique signature of the PSO family whose molecular basis is still unknown. The corresponding inhibition constants (K i ) at the optimal pH of β-Glcase (7.3) ranged from 5.5 to 26.4 μM ( Table   2 ), similar to that previously encountered for Glc-PSO-HHD (12 μM) [70] . Interestingly, the inhibition potency decreased from 2 to 11-fold when moving from pH 7.3 to 5.5, suggesting that the neutral form of the compounds is the most active species. Inhibition of bovine liver β-glucosidase is often used as a preliminary parameter to select candidates as pharmacological chaperones for mutant human GCase associated with Gaucher disease. Yet, the predictive character of the data must be taken with care: although both enzymes are members of the GHA clan in the CAzY classification [85] , meaning that they share three-dimensional structural similarities, they belong to different glycosyl hydrolase families, namely GH1 and GH30, with only limited sequence similarity [85] . Indeed, determination of the inhibition activity against human GCase (pH 7.0) revealed that the D-Gal-PSO representative 16
was inactive, whereas a strong influence of the terminal functional group at the hexadecyl aglycone chain was observed in the Glc-PSO series, the inhibitory potency decreasing in the sense F (15; IC 50 3.9 μM) > COOMe (12; IC 50 33 μM) > I (13; IC 50 230 μM) > COOH (17; IC 50 420 μM). The dimeric derivative 14 turned out to be inactive (Table 2) . No inhibition of other lysosomal enzymes, such as α-glucosidase, α-galactosidase, β-galactosidase, and β-hexosaminidase, was observed, reproducing the selectivity pattern already found in commercial enzymes. Most interestingly, an about one-order-of-magnitude decrease in the GCase inhibiton strength was also observed at pH 5 ( Table 2 ; see also Figure 2 for the most active compounds 15 and 12), a favorable feature for chaperone candidates.
(pH 7)
15 (pH 5)
12 (pH 5) The dramatic effect of the ω-substituent in the hexadecyl chain on the ability of PSO derivatives to inhibit GCase, above two orders of magnitude when comparing the fluoro and the carboxylic acid groups, reinforces our initial hypothesis that PSO:GCase complexes might be stabilized by a long-range interaction involving this terminal group and an amino acid residue located at a maximum distance of 22 Å from the catalytic site ( Figure 3 ). Comparing with Glc-PSO-HHD (IC 50 11.2 μM) [70] , where the ω-substituent is OH, only the fluoro (15) and methoxycarbonyl (12) derivatives exhibit comparable binding affinities, much higher that the iodo (13) or carboxylic acid (17) partners. It is interesting to speculate that the terminal group is acting as hydrogen bond acceptor and that optimizing this long-range hydrogen bonding interaction may provide a general strategy for the design of potent and specific GCase inhibitors/chaperones.
The IC 50 value for 15 is even lower as compared to that encountered for the reference chaperone drug ambroxol against GCase in a similar assay (4.1 μM) [70] . In normal cells, 12 and 15 had no effect on GCase activity. In N370S/N370S Gaucher fibroblasts ( Figure 4 ) compound 12 had only a marginal effect (12% activity increase at 30 μM concentration), whereas 15 up-regulated the activity of the mutant enzyme in a very significant manner (62% at 30 μM), actually more efficiently than the hydroxyl-bearing analogue Glc-PSO-HHD (55% at 90 μM). In a parallel assay, ABX led to a maximum activity enhancement of 33% at 10 μM [70] , with a decrease in the chaperone efficiency when increasing the concentration to 30 μM, meaning that the inhibitory activity overcomes the chaperone effect. In the case of 15, this situation occurred only at 60 μM, indicating a more favorable chaperone/inhibitor balance.
Neither 12 or 15 nor ABX or Glc-PSO-HHD were effective at increasing the activity in the case of the L444P/L444P mutant GCase, nor did they exhibit toxic effect on any of the normal or mutant cell lines assayed for 5 days of incubation. The ensemble of results supports the potential of the PSO scaffold for the design of selective β-Glc inhibitors and active site-directed pharmacological chaperones for Gaucher disease.
Although the observed activity enhancements do not surpass the values reported for the most efficient iminosugar-type chaperones [86] , they are in principle medically useful. Most importantly, they also provide a proof of concept that long-range non-glycone interactions can be advantageously exploited to endow a rigid pyranoid glycone moiety with high binding affinity and selectivity toward a given glycosidase and suggest a key structural element for the design of GCase chaperones. The current data also validate the synthetic methodology for the purpose of structure-activity relationship studies and pharmacological chaperone optimization.
Experimental section
General methods. All chemicals were reagent grade and used as supplied unless otherwise specified. TiO(CF 3 COO) 2 catalyst was prepared following a previously reported procedure [87] . (98 %, only α-epoxide). The crude could not be purified due the inherent instability of 1,2-anhydrosugars.
General procedure for the synthesis of cis-1,2-fused 1,3-oxazolidine-2-thione precursors 1 and 2 [76, 77] . To a stirred solution of the crude 1,2-anhydro-sugar 4 or 6 (1.00 mmol) and KSCN (3.00 mmol) in dry CH 3 CN (5 mL), finely powdered TiO(CF 3 COO) 2 (0.02 mmol) was added under an Ar atmosphere, and the mixture was heated to boiling for appropriate time.
After completion of the reaction (TLC monitoring), the mixture was cooled to room temperature, H 2 O (10 mL) was added and the resultant mixture was extracted with EtOAc (2 x 20 mL). The combined organic extracts were dried over MgSO 4 , filtered and concentrated. Flash chromatography on silica gel (ethyl acetate/hexanes 2:1) gave the bycyclic derivatives 1 or 2 (87 % and 79 %, respectively).
General procedure for the S-alkylation of cis-1,2-fused D-glycopyranose-1,3-oxazolidine-2-thione derivatives. To a solution of the 1,3-oxazolidine-2-thione derivative (1.00 mmol) in CH 2 Cl 2 (3.5 mL), the corresponding alkyl iodide (3.00 mmol), Et 3 N (3.00 mmol) and TBD (0.2 mmol) were added followed by stirring at room temperature. After completion of the reaction, the mixture was washed with saturated NaHCO 3 and brine, dried, and concentrated.
Chromatographic purification afforded the S-alkylated compounds in the yields shown. FT-IR (neat) υ in cm Reaction times were appropiated to obtain 10-20% conversion of the substrate in order to achieve linear rates. The absorbance of the resulting mixture was determined at 405 nm or 492 nm (for trehalase). Approximate values of K i were determined using a fixed concentration of substrate (around the K m value for the different glycosidases) and various concentrations of inhibitor. Full K i determinations and enzyme inhibition mode were determined from the slope of Lineweaver-Burk plots and double reciprocal analysis.
Lysosomal enzyme activity assay. Lysosomal enzyme activities in cell lysates were determined as described previously [88, 89] . Briefly, cells were scraped in ice-cold 0.1% Triton X-100 in water. After centrifugation (6,000 rpm for 15 min at 4 ºC) to remove insoluble materials, protein concentrations were determined using Protein Assay Rapid Kit (Wako, Tokyo, Japan).
The Cell culture and GCase activity enhancement assay. Human skin fibroblasts from a healthy and two Gaucher disease patients (with N370S/N370S and L444P/L444P mutations) were maintained in our laboratory with DMEM supplemented with 10% FBS as the culture medium.
For enzyme activity enhancement assay, cells were cultured in the presence of different concentrations of Glc-PSO derivatives 12 and 15 or DMSO alone (as a control) for 5 days and harvested by scraping [88, 89] . Cytotoxicity of the compounds was monitored by measuring the lactate dehydrogenase activities in the cultured supernatants (LDH assay kit, Wako, Tokyo, Japan).
Supporting information available:
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